MCRB
Income statement / Annual
Last year (2023), Seres Therapeutics, Inc.'s total revenue was $126.33 M,
an increase of 1,672.24% from the previous year.
In 2023, Seres Therapeutics, Inc.'s net income was -$113.72 M.
See Seres Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$126.33 M
|
$7.13 M
|
$144.93 M
|
$33.22 M
|
$34.51 M
|
$28.27 M
|
$32.10 M
|
$21.77 M
|
$0.00
|
$0.00
|
| Cost of Revenue |
$15.11 M |
$1.00 M |
$1.73 M |
$90.57 M |
$80.14 M |
$95.96 M |
$89.46 M |
$81.99 M |
$728,000.00 |
$10.72 M |
| Gross Profit |
$111.21 M |
$6.12 M |
$143.20 M |
-$57.36 M |
-$45.64 M |
-$67.69 M |
-$57.36 M |
-$60.22 M |
-$728,000.00 |
-$10.72 M |
| Gross Profit Ratio |
0.88 |
0.86 |
0.99 |
-1.73 |
-1.32 |
-2.39 |
-1.79 |
-2.77 |
0 |
0 |
| Research and Development
Expenses |
$145.86 M
|
$172.92 M
|
$141.89 M
|
$90.57 M
|
$80.14 M
|
$95.96 M
|
$89.46 M
|
$81.99 M
|
$38.10 M
|
$10.72 M
|
| General & Administrative
Expenses |
$87.74 M
|
$79.69 M
|
$69.26 M
|
$30.78 M
|
$24.75 M
|
$32.60 M
|
$34.04 M
|
$32.62 M
|
$16.76 M
|
$4.36 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$87.74 M
|
$79.69 M
|
$69.26 M
|
$30.78 M
|
$24.75 M
|
$32.60 M
|
$34.04 M
|
$32.62 M
|
$16.76 M
|
$4.36 M
|
| Other Expenses |
$15.11 M |
$1.00 M |
-$1.73 M |
$981,000.00 |
$1.07 M |
$170,000.00 |
$425,000.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$218.49 M |
$253.62 M |
$209.42 M |
$121.35 M |
$104.89 M |
$128.55 M |
$123.50 M |
$114.61 M |
$54.86 M |
$15.08 M |
| Cost And Expenses |
$233.60 M |
$253.62 M |
$209.42 M |
$121.35 M |
$104.89 M |
$128.55 M |
$123.50 M |
$114.61 M |
$54.86 M |
$15.08 M |
| Interest Income |
$7.30 M |
$3.06 M |
$2.87 M |
$946,000.00 |
$1.03 M |
$0.00 |
$0.00 |
$2.23 M |
$638,000.00 |
$0.00 |
| Interest Expense |
$13.18 M |
$6.02 M |
$2.91 M |
$2.92 M |
$502,000.00 |
$1.17 M |
$1.59 M |
$969,000.00 |
$555,000.00 |
$0.00 |
| Depreciation &
Amortization |
$15.11 M
|
$11.85 M
|
$9.22 M
|
$8.89 M
|
$9.83 M
|
$7.86 M
|
$7.26 M
|
$4.21 M
|
$728,000.00
|
$190,000.00
|
| EBITDA |
-$92.17 M
|
-$244.14 M
|
-$62.67 M
|
-$86.20 M
|
-$68.29 M
|
-$100.28 M
|
-$84.14 M
|
-$86.41 M
|
-$54.85 M
|
-$13.47 M
|
| EBITDA Ratio |
-0.73 |
-34.25 |
-0.43 |
-2.6 |
-1.98 |
-3.55 |
-2.62 |
-3.97 |
0 |
0 |
| Operating Income Ratio
|
-0.85
|
-34.58
|
-0.45
|
-2.65
|
-2.08
|
-3.55
|
-2.85
|
-4.27
|
0
|
0
|
| Total Other
Income/Expenses Net |
-$6.45 M
|
-$3.67 M
|
-$1.09 M
|
-$997,000.00
|
$1.60 M
|
$170,000.00
|
$425,000.00
|
$1.26 M
|
-$7,000.00
|
-$1.42 M
|
| Income Before Tax |
-$113.72 M |
-$250.16 M |
-$65.58 M |
-$89.13 M |
-$70.28 M |
-$98.94 M |
-$89.38 M |
-$91.58 M |
-$54.78 M |
-$16.71 M |
| Income Before Tax Ratio
|
-0.9
|
-35.09
|
-0.45
|
-2.68
|
-2.04
|
-3.5
|
-2.78
|
-4.21
|
0
|
0
|
| Income Tax Expense |
$14.95 M |
$3.67 M |
-$4.08 M |
-$2.67 M |
-$6.04 M |
$1.34 M |
-$1.59 M |
$2.23 M |
-$804,000.00 |
$1.63 M |
| Net Income |
-$113.72 M |
-$253.82 M |
-$61.50 M |
-$86.45 M |
-$64.24 M |
-$98.94 M |
-$89.38 M |
-$91.58 M |
-$54.78 M |
-$16.71 M |
| Net Income Ratio |
-0.9 |
-35.61 |
-0.42 |
-2.6 |
-1.86 |
-3.5 |
-2.78 |
-4.21 |
0 |
0 |
| EPS |
-0.89 |
-2.35 |
-0.67 |
-1.08 |
-1.13 |
-2.43 |
-2.21 |
-2.3 |
-2.33 |
-0.56 |
| EPS Diluted |
-0.89 |
-2.35 |
-0.67 |
-1.08 |
-1.13 |
-2.43 |
-2.21 |
-2.3 |
-2.33 |
-0.56 |
| Weighted Average Shares
Out |
$128.00 M
|
$108.08 M
|
$91.70 M
|
$79.79 M
|
$56.65 M
|
$40.74 M
|
$40.45 M
|
$39.85 M
|
$23.53 M
|
$29.78 M
|
| Weighted Average Shares
Out Diluted |
$128.00 M
|
$108.08 M
|
$91.70 M
|
$79.79 M
|
$56.65 M
|
$40.74 M
|
$40.45 M
|
$39.85 M
|
$23.53 M
|
$29.78 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
